Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Nov 3;11:186. doi: 10.1186/1743-422X-11-186

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Lovato et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Schematic representation of the infectious GALV-Nf cDNA clones. GALV-Nf sequences under the control of T7 promoter (T7-GALV-Nf and T7-MCS.GALV-Nf) were linearized with SrfI and used for the in vitro production of infectious transcripts (details of T7 transcription site and SrfI cleavage site are shown in panel A). A polylinker was inserted by BstBI cleavage in the T7-GALV-Nf construct obtaining the T7-MCS.GALV-Nf vector (the BglII and XhoI sites of the polylinker are shown in bold and underlined in the sequence reported in panel B). The viral sequence, placed under the control of the CaMV 35S promoter (35S) and the nos terminator (NOS), was introduced (using SacI/AscI and AsiSI/XbaI sites) between the pK7WG2 left and right borders (RB and LB) producing the pK7WG2-MCS.HRz.GALV-Nf binary vector for A. tumefaciens-mediated infection. To design a functional 5′ viral end, the junction between the 35S and the viral sequence was obtained by ligating blunt-end fragments produced by digesting the 35S sequence with StuI and the viral sequence with DraI (details shown in panel C). The sequence of the Hepatitis delta virus antigenomic ribozyme (HRz) was introduced to allow the production of a correct 3′ viral end following ribozyme autocleavage (panel C). T7: T7 promoter; p33 and p92: RNA-dependent RNA polymerases; p40: coat protein (CP); p24: movement protein (MP); p19: silencing suppressor.